Should I buy or sell OpGen stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares. View OPGN analyst ratings or view top-rated stocks .

How have OPGN shares performed in 2024?

OpGen's stock was trading at $0.42 on January 1st, 2024. Since then, OPGN shares have increased by 46.7% and is now trading at $0.6161. View the best growth stocks for 2024 here .

Are investors shorting OpGen?

OpGen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,230,000 shares, an increase of 10,621.2% from the March 15th total of 20,800 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 1.3 days. Currently, 22.4% of the company's stock are sold short. View OpGen's Short Interest .

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OPGN earnings forecast .

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative net margin of 852.18% and a negative trailing twelve-month return on equity of 316.30%. During the same period in the previous year, the firm posted ($2.60) EPS.

When did OpGen's stock split?

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of OpGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL) , Sorrento Therapeutics (SRNE) , Energy Transfer (ET) , Vaxart (VXRT) , VBI Vaccines (VBIV) , Nabriva Therapeutics (NBRV) , SCYNEXIS (SCYX) , Agile Therapeutics (AGRX) , Pfizer (PFE) and Inovio Pharmaceuticals (INO) .

OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free OPGN Stock Alerts

$0.62

+0.02 (+3.36%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.57
▼
$0.62
50-Day Range: $0.38
▼
$0.78
52-Week Range: $0.17
▼
$3.84

Volume: 204,331 shs
Average Volume: 1.47 million shs
Market Capitalization: $6.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get OpGen alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About OpGen Stock (NASDAQ:OPGN)

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OPGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPGN Stock News Headlines

April 14, 2024 | americanbankingnews.com

OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

March 28, 2024 | msn.com

Shares Rip In Reaction To Activist Investor Becoming CEO

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | msn.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.08%

March 26, 2024 | markets.businessinsider.com

Dow Gains 100 Points; McCormick Posts Upbeat Results

March 26, 2024 | markets.businessinsider.com

Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February

March 26, 2024 | msn.com

Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates

March 26, 2024 | msn.com

Why Is Penny Stock OpGen Trading Higher On Tuesday?

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 26, 2024 | marketwatch.com

OpGen Investor David Lazar Is Named CEO

March 25, 2024 | globenewswire.com

OpGen Announces Acquisition of Preferred Stock by David Lazar

March 20, 2024 | money.usnews.com

Opgen Inc

February 9, 2024 | msn.com

OpGen Inc Reports Unregistered Equity Sales Update

February 9, 2024 | msn.com

OpGen Inc. Extends Warrant Exercise Deadline to 2024

December 17, 2023 | morningstar.com

OpGen Inc OPGN

December 13, 2023 | bizjournals.com

Rockville biotech OpGen fights to retain Nasdaq listing as business teeters

November 15, 2023 | bizjournals.com

Rockville biotech OpGen shrinks headcount, scales down U.S. operations

November 15, 2023 | finanznachrichten.de

OpGen, Inc.: OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

November 14, 2023 | markets.businessinsider.com

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

October 12, 2023 | seekingalpha.com

OpGen surges after announcing private placement

October 12, 2023 | finance.yahoo.com

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

October 12, 2023 | uk.finance.yahoo.com

OpGen, Inc. (OPGN) interactive stock chart – Yahoo Finance

October 12, 2023 | marketwatch.com

OpGen Shares Take Flight Premarket on Talks for Potential Deal

October 12, 2023 | investorplace.com

Why Is OpGen (OPGN) Stock Up 540% Today?

September 29, 2023 | markets.businessinsider.com

Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket

August 14, 2023 | msn.com

HC Wainwright downgrades OpGen amid bankruptcy concerns

August 13, 2023 | finance.yahoo.com

OpGen, Inc. (NASDAQ:OPGN) Q2 2023 Earnings Call Transcript

See More Headlines

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:OPGN
CUSIP: N/A
CIK: 1293818
Web: www.opgen.com
Phone: (240) 813-1260
Fax: 301-869-9684
Employees: 85
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($6.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,280,000.00
Net Margins: -852.18%
Pretax Margin: -852.18%
Return on Equity: -316.30%
Return on Assets: -89.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.28
Quick Ratio: 0.18

Sales & Book Value

Annual Sales: $2.61 million
Price / Sales: 2.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.61 per share
Price / Book: 0.24

Miscellaneous

Outstanding Shares: 10,010,000
Free Float: 9,881,000
Market Cap: $6.17 million
Optionable: Not Optionable
Beta: -0.71

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Oliver Schacht Ph.D. (Age 53)
CEO, President & Director
Comp: $408k
Mr. Albert Weber (Age 61)
CFO & Corporate Secretary
Comp: $317.5k
Mr. Johannes Bacher (Age 55)
Chief Operating Officer
Comp: $300k
Mr. Vadim Sapiro (Age 53)
Chief Information Officer
Comp: $300k

Key Competitors

View All Competitors

OPGN Stock Analysis - Frequently Asked Questions

Should I buy or sell OpGen stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares.
View OPGN analyst ratings or view top-rated stocks.
How have OPGN shares performed in 2024?: OpGen's stock was trading at $0.42 on January 1st, 2024. Since then, OPGN shares have increased by 46.7% and is now trading at $0.6161.
View the best growth stocks for 2024 here.
Are investors shorting OpGen?: OpGen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,230,000 shares, an increase of 10,621.2% from the March 15th total of 20,800 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 1.3 days. Currently, 22.4% of the company's stock are sold short.
View OpGen's Short Interest.
When is OpGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OPGN earnings forecast.
How were OpGen's earnings last quarter?: OpGen, Inc. (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative net margin of 852.18% and a negative trailing twelve-month return on equity of 316.30%. During the same period in the previous year, the firm posted ($2.60) EPS.

When did OpGen's stock split?: OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of OpGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).
When did OpGen IPO?: OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.
How do I buy shares of OpGen?: Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial